Tags

Type your tag names separated by a space and hit enter

Heterogeneous expression of ACE2 and TMPRRS2 in mesenchymal stromal cells.
J Cell Mol Med. 2022 01; 26(1):228-234.JC

Abstract

The outbreak of COVID-19 has become a serious public health emergency. The virus targets cells by binding the ACE2 receptor. After infection, the virus triggers in some humans an immune storm containing the release of proinflammatory cytokines and chemokines followed by multiple organ failure. Several vaccines are enrolled, but an effective treatment is still missing. Mesenchymal stem cells (MSCs) have shown to secrete immunomodulatory factors that suppress this cytokine storm. Therefore, MSCs have been suggested as a potential treatment option for COVID-19. We report here that the ACE2 expression is minimal or nonexistent in MSC derived from three different human tissue sources (adipose tissue, umbilical cord Wharton`s jelly and bone marrow). In contrast, TMPRSS2 that is implicated in SARS-CoV-2 entry has been detected in all MSC samples. These results are of particular importance for future MSC-based cell therapies to treat severe cases after COVID-19 infection.

Links

PMC Free PDF

Authors+Show Affiliations

Generali M
Institute for Regenerative Medicine (IREM), Center for Therapy Development and Good Manufacturing Practice, University of Zurich, Zurich, Switzerland.
Kehl D
Institute for Regenerative Medicine (IREM), Center for Therapy Development and Good Manufacturing Practice, University of Zurich, Zurich, Switzerland.
Wanner D
Institute for Regenerative Medicine (IREM), Center for Therapy Development and Good Manufacturing Practice, University of Zurich, Zurich, Switzerland.
Okoniewski MJ
Scientific IT Services ETH Zurich, ETH Zurich, Zürich, Switzerland.
Hoerstrup SP
Institute for Regenerative Medicine (IREM), Center for Therapy Development and Good Manufacturing Practice, University of Zurich, Zurich, Switzerland. Center for Applied Biotechnology and Molecular Medicine (CABMM), University of Zurich, Zurich, Switzerland. Wyss Zurich, University of Zurich and ETH Zurich, Zurich, Switzerland.
Cinelli P
Center for Applied Biotechnology and Molecular Medicine (CABMM), University of Zurich, Zurich, Switzerland. Department of Trauma Surgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

MeSH

Adipose TissueAngiotensin-Converting Enzyme 2Bone Marrow CellsCOVID-19Cell- and Tissue-Based TherapyCytokine Release SyndromeGene Expression ProfilingGene Expression RegulationHumansMesenchymal Stem Cell TransplantationMesenchymal Stem CellsPrimary Cell CultureProtein BindingSARS-CoV-2Serine EndopeptidasesSpike Glycoprotein, CoronavirusUmbilical Cord

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

34821008

Citation

Generali, Melanie, et al. "Heterogeneous Expression of ACE2 and TMPRRS2 in Mesenchymal Stromal Cells." Journal of Cellular and Molecular Medicine, vol. 26, no. 1, 2022, pp. 228-234.
Generali M, Kehl D, Wanner D, et al. Heterogeneous expression of ACE2 and TMPRRS2 in mesenchymal stromal cells. J Cell Mol Med. 2022;26(1):228-234.
Generali, M., Kehl, D., Wanner, D., Okoniewski, M. J., Hoerstrup, S. P., & Cinelli, P. (2022). Heterogeneous expression of ACE2 and TMPRRS2 in mesenchymal stromal cells. Journal of Cellular and Molecular Medicine, 26(1), 228-234. https://doi.org/10.1111/jcmm.17048
Generali M, et al. Heterogeneous Expression of ACE2 and TMPRRS2 in Mesenchymal Stromal Cells. J Cell Mol Med. 2022;26(1):228-234. PubMed PMID: 34821008.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Heterogeneous expression of ACE2 and TMPRRS2 in mesenchymal stromal cells. AU - Generali,Melanie, AU - Kehl,Debora, AU - Wanner,Debora, AU - Okoniewski,Michal J, AU - Hoerstrup,Simon P, AU - Cinelli,Paolo, Y1 - 2021/11/24/ PY - 2021/10/19/revised PY - 2021/07/16/received PY - 2021/10/25/accepted PY - 2021/11/26/pubmed PY - 2022/1/22/medline PY - 2021/11/25/entrez KW - adult stem cells KW - cellular therapy KW - mesenchymal stromal cells (MSCs) KW - sars-CoV-2 SP - 228 EP - 234 JF - Journal of cellular and molecular medicine JO - J Cell Mol Med VL - 26 IS - 1 N2 - The outbreak of COVID-19 has become a serious public health emergency. The virus targets cells by binding the ACE2 receptor. After infection, the virus triggers in some humans an immune storm containing the release of proinflammatory cytokines and chemokines followed by multiple organ failure. Several vaccines are enrolled, but an effective treatment is still missing. Mesenchymal stem cells (MSCs) have shown to secrete immunomodulatory factors that suppress this cytokine storm. Therefore, MSCs have been suggested as a potential treatment option for COVID-19. We report here that the ACE2 expression is minimal or nonexistent in MSC derived from three different human tissue sources (adipose tissue, umbilical cord Wharton`s jelly and bone marrow). In contrast, TMPRSS2 that is implicated in SARS-CoV-2 entry has been detected in all MSC samples. These results are of particular importance for future MSC-based cell therapies to treat severe cases after COVID-19 infection. SN - 1582-4934 UR - https://www.unboundmedicine.com/medline/citation/34821008/Heterogeneous_expression_of_ACE2_and_TMPRRS2_in_mesenchymal_stromal_cells_ DB - PRIME DP - Unbound Medicine ER -